Business Update

Gene-based company to list on NASDAQ

Published in Biotech Business Week, July 25th, 2005

ChemGenex Pharmaceuticals, Ltd., has received approval from the NASDAQ to list its securities on the NASDAQ SmallCap Market as American Depositary Receipts (ADRs) under the ticker CXSP.

Trading in ChemGenex ADRs was slated to begin Tuesday June 28, 2005.

Each ADR will represent 15 ordinary shares. The ordinary shares will continue to trade on the Australian Stock Exchange under the ASX code "CXS." The company has selected the Bank of New York to administer its ADR program.

"This is an important step in the growth of ChemGenex as an international pharmaceutical company," said Greg Collier, PhD, CEO and managing director of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2005-07-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry